TOKENPOST
1 min read
Add as a preferred source on Google

Lilly Says Retatrutide Reduced A1C and Produced Weight Loss in Phase 3 Trial

The company said the treatment reduced A1C, a biomarker associated with diabetes, alongside weight loss.

By John Kim
Published
A gloved hand places an unlabeled sample tube in a rack / TokenPost.ai
A gloved hand places an unlabeled sample tube in a rack / TokenPost.ai

Eli Lilly said Wednesday, Oct. 28, that retatrutide produced weight loss and reduced A1C in a Phase 3 trial.

A1C is a biomarker associated with diabetes.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…